In combination with prednisone, abiraterone is indicated to treat metastatic castration-resistant prostate cancer (mCRPC): co-administration with prednisone decreases the incidence and severity of adverse side effects
Contraindications
Liver Disease
Pharmacology
CYP17 Inhibitor: androgen biosynthesis inhibitor in prostate, tetes, and adrenal glands
Decreased serum testosterone and other androgens
Mineralocorticoid excess -> results in side efefcts of hypertension, hypokalemia, and fluid retention